An unexpected and lasting response to immunotherapy in esophageal cancer
Published: · Last updated:
Original article: Durable pembrolizumab response in metastatic MSS ARID1A-mutant undifferentiated carcinoma of the esophagus. J Chemother, 2025
A case report describing a long-lasting response in a patient who was not expected to benefit from immunotherapy because of a genetic feature.